Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

4 Ds in health research-working together toward rapid precision medicine.

Niederberger E, Parnham MJ, Maas J, Geisslinger G.

EMBO Mol Med. 2019 Sep 18:e10917. doi: 10.15252/emmm.201910917. [Epub ahead of print]

2.

5-Amino-1-β-D-Ribofuranosyl-Imidazole-4-Carboxamide (AICAR) Reduces Peripheral Inflammation by Macrophage Phenotype Shift.

Martin LM, Möller M, Weiss U, Russe OQ, Scholich K, Pierre S, Geisslinger G, Niederberger E.

Int J Mol Sci. 2019 Jul 2;20(13). pii: E3255. doi: 10.3390/ijms20133255.

3.

Inhibition of the protein kinase IKKepsilon attenuates neuropathic pain in mice.

Möser CV, Möller M, Fleck SC, Thomas D, Geisslinger G, Niederberger E.

Neuropharmacology. 2019 Mar 1;146:198-211. doi: 10.1016/j.neuropharm.2018.12.004. Epub 2018 Dec 6.

PMID:
30528326
4.

Treatment Seeking and Ebola Community Care Centers in Sierra Leone: A Qualitative Study.

Carter SE, O'Reilly M, Frith-Powell J, Umar Kargbo A, Byrne D, Niederberger E.

J Health Commun. 2017;22(sup1):66-71. doi: 10.1080/10810730.2016.1216204.

PMID:
28854139
5.

Barriers and Enablers to Treatment-Seeking Behavior and Causes of High-Risk Practices in Ebola: A Case Study From Sierra Leone.

Carter SE, O'Reilly M, Walden V, Frith-Powell J, Umar Kargbo A, Niederberger E.

J Health Commun. 2017;22(sup1):31-38. doi: 10.1080/10810730.2016.1222034.

PMID:
28854134
6.

Drugging the pain epigenome.

Niederberger E, Resch E, Parnham MJ, Geisslinger G.

Nat Rev Neurol. 2017 Jul;13(7):434-447. doi: 10.1038/nrneurol.2017.68. Epub 2017 May 26. Review.

PMID:
28548108
7.

AMPK contributes to aerobic exercise-induced antinociception downstream of endocannabinoids.

King-Himmelreich TS, Möser CV, Wolters MC, Schmetzer J, Schreiber Y, Ferreirós N, Russe OQ, Geisslinger G, Niederberger E.

Neuropharmacology. 2017 Sep 15;124:134-142. doi: 10.1016/j.neuropharm.2017.05.002. Epub 2017 May 4.

PMID:
28479394
8.

AMP-activated kinase and the endogenous endocannabinoid system might contribute to antinociceptive effects of prolonged moderate caloric restriction in mice.

King-Himmelreich TS, Möser CV, Wolters MC, Schmetzer J, Möller M, Schreiber Y, Ferreirós N, Geisslinger G, Niederberger E.

Mol Pain. 2017 Jan;13:1744806917703111. doi: 10.1177/1744806917703111.

9.

Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.

Grösch S, Niederberger E, Geisslinger G.

Expert Opin Investig Drugs. 2017 Jan;26(1):51-61. doi: 10.1080/13543784.2017.1260544. Epub 2016 Nov 20. Review.

PMID:
27841017
10.

Cleavage of SNAP-25 ameliorates cancer pain in a mouse model of melanoma.

Olbrich K, Costard L, Möser CV, Syhr KM, King-Himmelreich TS, Wolters MC, Schmidtko A, Geisslinger G, Niederberger E.

Eur J Pain. 2017 Jan;21(1):101-111. doi: 10.1002/ejp.904. Epub 2016 Jun 15.

PMID:
27301493
11.

The impact of endurance exercise on global and AMPK gene-specific DNA methylation.

King-Himmelreich TS, Schramm S, Wolters MC, Schmetzer J, Möser CV, Knothe C, Resch E, Peil J, Geisslinger G, Niederberger E.

Biochem Biophys Res Commun. 2016 May 27;474(2):284-290. doi: 10.1016/j.bbrc.2016.04.078. Epub 2016 Apr 18.

PMID:
27103439
12.

The protein kinase IKKepsilon contributes to tumour growth and tumour pain in a melanoma model.

Möser CV, Meissner M, Laarmann K, Olbrich K, King-Himmelreich TS, Wolters MC, Geisslinger G, Niederberger E.

Biochem Pharmacol. 2016 Mar 1;103:64-73. doi: 10.1016/j.bcp.2015.12.016. Epub 2016 Jan 12.

PMID:
26793999
13.

Age-Dependent Changes in the Inflammatory Nociceptive Behavior of Mice.

King-Himmelreich TS, Möser CV, Wolters MC, Olbrich K, Geisslinger G, Niederberger E.

Int J Mol Sci. 2015 Nov 18;16(11):27508-19. doi: 10.3390/ijms161126041.

14.

Computational functional genomics based analysis of pain-relevant micro-RNAs.

Lötsch J, Niederberger E, Ultsch A.

Hum Genet. 2015 Nov;134(11-12):1221-38. doi: 10.1007/s00439-015-1600-3. Epub 2015 Sep 18.

PMID:
26385553
15.

[Pharmacological aspects of pain research in Germany].

Niederberger E, Kuner R, Geißlinger G.

Schmerz. 2015 Oct;29(5):531-8. doi: 10.1007/s00482-015-0042-0. Review. German.

PMID:
26294077
16.

Activation of AMPK and its Impact on Exercise Capacity.

Niederberger E, King TS, Russe OQ, Geisslinger G.

Sports Med. 2015 Nov;45(11):1497-509. doi: 10.1007/s40279-015-0366-z. Review.

PMID:
26186961
17.

AMP-activated protein kinase is activated by non-steroidal anti-inflammatory drugs.

King TS, Russe OQ, Möser CV, Ferreirós N, Kynast KL, Knothe C, Olbrich K, Geisslinger G, Niederberger E.

Eur J Pharmacol. 2015 Sep 5;762:299-305. doi: 10.1016/j.ejphar.2015.06.001. Epub 2015 Jun 3.

PMID:
26049010
18.

TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.

Möser CV, Stephan H, Altenrath K, Kynast KL, Russe OQ, Olbrich K, Geisslinger G, Niederberger E.

J Neuroinflammation. 2015 May 23;12:100. doi: 10.1186/s12974-015-0319-3.

19.

Lack of effect of a P2Y6 receptor antagonist on neuropathic pain behavior in mice.

Syhr KM, Kallenborn-Gerhardt W, Lu R, Olbrich K, Schmitz K, Männich J, Ferreiros-Bouzas N, Geisslinger G, Niederberger E, Schmidtko A.

Pharmacol Biochem Behav. 2014 Sep;124:389-95. doi: 10.1016/j.pbb.2014.07.009. Epub 2014 Jul 18.

PMID:
25042778
20.

LPS inhibits caspase 3-dependent apoptosis in RAW264.7 macrophages induced by the AMPK activator AICAR.

Russe OQ, Möser CV, Kynast KL, King TS, Olbrich K, Grösch S, Geisslinger G, Niederberger E.

Biochem Biophys Res Commun. 2014 May 9;447(3):520-5. doi: 10.1016/j.bbrc.2014.04.008. Epub 2014 Apr 13.

PMID:
24732361
21.

PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis.

Schiffmann S, Weigert A, Männich J, Eberle M, Birod K, Häussler A, Ferreiros N, Schreiber Y, Kunkel H, Grez M, Weichand B, Brüne B, Pfeilschifter W, Nüsing R, Niederberger E, Grösch S, Scholich K, Geisslinger G.

Biochem Pharmacol. 2014 Feb 15;87(4):625-35. doi: 10.1016/j.bcp.2013.12.006. Epub 2013 Dec 16.

PMID:
24355567
22.

[Epigenetics and pain].

Niederberger E.

Anaesthesist. 2014 Jan;63(1):63-9. doi: 10.1007/s00101-013-2274-7. Review. German.

PMID:
24337072
23.

Activation of the AMP-activated protein kinase reduces inflammatory nociception.

Russe OQ, Möser CV, Kynast KL, King TS, Stephan H, Geisslinger G, Niederberger E.

J Pain. 2013 Nov;14(11):1330-40. doi: 10.1016/j.jpain.2013.05.012. Epub 2013 Jul 31.

PMID:
23916727
24.

Novel findings in pain processing pathways: implications for miRNAs as future therapeutic targets.

Kynast KL, Russe OQ, Geisslinger G, Niederberger E.

Expert Rev Neurother. 2013 May;13(5):515-25. doi: 10.1586/ern.13.34. Review.

PMID:
23621309
25.

Proteomics and NF-κB: an update.

Niederberger E, Geisslinger G.

Expert Rev Proteomics. 2013 Apr;10(2):189-204. doi: 10.1586/epr.13.5. Review.

PMID:
23573785
26.

Anatomical variations of the anterior cerebral arterial circle visualized by multidetector computed tomography angiography: comparison with 3D rotational angiography.

Ferré JC, Niederberger E, Morandi X, Raoult H, Carsin-Nicol B, Gauvrit JY.

J Neuroradiol. 2013 May;40(2):112-20. doi: 10.1016/j.neurad.2012.05.009. Epub 2013 Feb 20.

PMID:
23433676
27.

Modulation of central nervous system-specific microRNA-124a alters the inflammatory response in the formalin test in mice.

Kynast KL, Russe OQ, Möser CV, Geisslinger G, Niederberger E.

Pain. 2013 Mar;154(3):368-76. doi: 10.1016/j.pain.2012.11.010. Epub 2012 Nov 24.

PMID:
23318130
28.

Current role of CT and whole body MRI in multiple myeloma.

Duvauferrier R, Valence M, Patrat-Delon S, Brillet E, Niederberger E, Marchand A, Rescan M, Guillin R, Decaux O.

Diagn Interv Imaging. 2013 Feb;94(2):169-83. doi: 10.1016/j.diii.2012.12.001. Epub 2013 Jan 5.

29.

The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs.

Niederberger E, Möser CV, Kynast KL, Geisslinger G.

Curr Mol Med. 2013 Aug;13(7):1089-97. Review.

PMID:
23157677
30.

Altered gene expression in the prefrontal cortex of young rats induced by the ADHD drug atomoxetine.

Lempp T, Toennes SW, Wunder C, Russe OQ, Möser CV, Kynast KL, Freitag CM, Niederberger E.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:221-8. doi: 10.1016/j.pnpbp.2012.08.012. Epub 2012 Aug 30.

PMID:
22960082
31.

NADPH oxidase-4 maintains neuropathic pain after peripheral nerve injury.

Kallenborn-Gerhardt W, Schröder K, Del Turco D, Lu R, Kynast K, Kosowski J, Niederberger E, Shah AM, Brandes RP, Geisslinger G, Schmidtko A.

J Neurosci. 2012 Jul 25;32(30):10136-45. doi: 10.1523/JNEUROSCI.6227-11.2012.

32.

Imaging of snapping phenomena.

Guillin R, Marchand AJ, Roux A, Niederberger E, Duvauferrier R.

Br J Radiol. 2012 Oct;85(1018):1343-53. doi: 10.1259/bjr/52009417. Epub 2012 Jun 27. Review.

33.

The p21-activated kinase PAK 5 is involved in formalin-induced nociception through regulation of MAP-kinase signaling and formalin-specific receptors.

Coste O, Möser CV, Sisignano M, Kynast KL, Minden A, Geisslinger G, Niederberger E.

Behav Brain Res. 2012 Sep 1;234(1):121-8. doi: 10.1016/j.bbr.2012.06.017. Epub 2012 Jun 23.

PMID:
22732262
34.

Inhibitor kappa B kinase beta dependent cytokine upregulation in nociceptive neurons contributes to nociceptive hypersensitivity after sciatic nerve injury.

Kanngiesser M, Häussler A, Myrczek T, Küsener N, Lim HY, Geisslinger G, Niederberger E, Tegeder I.

J Pain. 2012 May;13(5):485-97. doi: 10.1016/j.jpain.2012.02.010.

PMID:
22564672
35.

The protein kinase IKKε is a potential target for the treatment of inflammatory hyperalgesia.

Möser CV, Kynast K, Baatz K, Russe OQ, Ferreirós N, Costiuk H, Lu R, Schmidtko A, Tegeder I, Geisslinger G, Niederberger E.

J Immunol. 2011 Sep 1;187(5):2617-25. doi: 10.4049/jimmunol.1004088. Epub 2011 Aug 3.

36.

Nerve injury evoked loss of latexin expression in spinal cord neurons contributes to the development of neuropathic pain.

Kühlein HN, Tegeder I, Möser C, Lim HY, Häussler A, Spieth K, Jennes I, Marschalek R, Beckhaus T, Karas M, Fauth M, Ehnert C, Geisslinger G, Niederberger E.

PLoS One. 2011 Apr 29;6(4):e19270. doi: 10.1371/journal.pone.0019270.

37.

MicroRNAs as new players in the pain game.

Niederberger E, Kynast K, Lötsch J, Geisslinger G.

Pain. 2011 Jul;152(7):1455-8. doi: 10.1016/j.pain.2011.01.042. Epub 2011 Feb 24. No abstract available.

PMID:
21353390
38.

Analysis of NF-kappaB signaling pathways by proteomic approaches.

Niederberger E, Geisslinger G.

Expert Rev Proteomics. 2010 Apr;7(2):189-203. doi: 10.1586/epr.10.1. Review.

PMID:
20377387
39.

Anatomic variants of the anterior part of the cerebral arterial circle at multidetector computed tomography angiography.

Niederberger E, Gauvrit JY, Morandi X, Carsin-Nicol B, Gauthier T, Ferré JC.

J Neuroradiol. 2010 Jul;37(3):139-47. doi: 10.1016/j.neurad.2009.12.004. Epub 2010 Mar 25. Review.

PMID:
20346510
40.

Cofilin phosphorylation is involved in nitric oxide/cGMP-mediated nociception.

Zulauf L, Coste O, Marian C, Möser C, Brenneis C, Niederberger E.

Biochem Biophys Res Commun. 2009 Dec 25;390(4):1408-13. doi: 10.1016/j.bbrc.2009.10.166. Epub 2009 Nov 5.

PMID:
19896457
41.

Update on the pathobiology of neuropathic pain.

Niederberger E, Kühlein H, Geisslinger G.

Expert Rev Proteomics. 2008 Dec;5(6):799-818. doi: 10.1586/14789450.5.6.799. Review.

PMID:
19086860
42.

cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I.

Schmidtko A, Gao W, König P, Heine S, Motterlini R, Ruth P, Schlossmann J, Koesling D, Niederberger E, Tegeder I, Friebe A, Geisslinger G.

J Neurosci. 2008 Aug 20;28(34):8568-76. doi: 10.1523/JNEUROSCI.2128-08.2008.

43.

The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?

Niederberger E, Geisslinger G.

FASEB J. 2008 Oct;22(10):3432-42. doi: 10.1096/fj.08-109355. Epub 2008 Jun 17. Review.

PMID:
18559989
44.

Cysteine-rich protein 2, a novel downstream effector of cGMP/cGMP-dependent protein kinase I-mediated persistent inflammatory pain.

Schmidtko A, Gao W, Sausbier M, Rauhmeier I, Sausbier U, Niederberger E, Scholich K, Huber A, Neuhuber W, Allescher HD, Hofmann F, Tegeder I, Ruth P, Geisslinger G.

J Neurosci. 2008 Feb 6;28(6):1320-30. doi: 10.1523/JNEUROSCI.5037-07.2008.

45.

Proteomics in neuropathic pain research.

Niederberger E, Geisslinger G.

Anesthesiology. 2008 Feb;108(2):314-23. doi: 10.1097/01.anes.0000299838.13368.6e.

PMID:
18212577
46.

The impact of CREB and its phosphorylation at Ser142 on inflammatory nociception.

Niederberger E, Ehnert C, Gao W, Coste O, Schmidtko A, Popp L, Gall CV, Korf HW, Tegeder I, Geisslinger G.

Biochem Biophys Res Commun. 2007 Oct 12;362(1):75-80. doi: 10.1016/j.bbrc.2007.07.148. Epub 2007 Aug 6.

PMID:
17692820
47.

The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice.

Metzner J, Popp L, Marian C, Schmidt R, Manderscheid C, Renne C, Fisslthaler B, Fleming I, Busse R, Geisslinger G, Niederberger E.

J Mol Med (Berl). 2007 Jun;85(6):623-33. Epub 2007 Feb 22.

PMID:
17318614
48.

Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB.

Niederberger E, Schmidtko A, Gao W, Kühlein H, Ehnert C, Geisslinger G.

Eur J Pharmacol. 2007 Mar 15;559(1):55-60. Epub 2006 Dec 12.

PMID:
17217946
49.

The glutamate transporter GLAST is involved in spinal nociceptive processing.

Niederberger E, Schmidtko A, Coste O, Marian C, Ehnert C, Geisslinger G.

Biochem Biophys Res Commun. 2006 Jul 28;346(2):393-9. Epub 2006 Jun 5.

PMID:
16765320
50.

Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.

Niederberger E, Manderscheid C, Geisslinger G.

Biochem Biophys Res Commun. 2006 Apr 14;342(3):940-8.

PMID:
16598848

Supplemental Content

Loading ...
Support Center